Ionis Pharmaceuticals Moves Forward with Angelman Syndrome Drug Trial Enrollment Completion
Ionis Pharmaceuticals completes enrollment for its Angelman syndrome drug trial, marking a significant milestone for the company.
Pfizer Faces Uncertainty: HSBC Downgrade vs. BMO's Outperform Stance
HSBC's downgrade puts pressure on Pfizer, while BMO Capital Markets remains optimistic. The market's reaction could shape investor sentiment.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Canada Diagnostic Centres Expands Operations with Shift Imaging Acquisition
Canada Diagnostic Centres enhances its diagnostic imaging network with the acquisition of Shift Imaging.
Ondas Holdings Expands Portfolio with $875.8M Acquisition of DZYNE
Ondas Holdings is set to acquire DZYNE for $875.8M, marking a significant move in the defense sector.
Solstice's $14.5B Acquisition of Element Solutions: A Game-Changer in Critical Minerals
Solstice Advanced Materials confirms a $14.5B acquisition of Element Solutions, reshaping the critical minerals landscap…
Vera Therapeutics Sees Stock Surge Ahead of Critical FDA Decision on Atacicept
Vera Therapeutics' stock jumped ahead of a pivotal FDA decision on atacicept, snapping a three-session slide and signali…
Prestige Consumer Healthcare's Successful LaCorium Acquisition and Debt Financing
Prestige Consumer Healthcare strengthens its portfolio with LaCorium acquisition and a $400M senior notes offering.
Incyte's Strategic Acquisition of Vega Therapeutics Enhances Hematology Portfolio
Incyte's acquisition of Vega Therapeutics marks a significant strategic move to bolster its hematology portfolio and mar…
AXT Inc. Secures Multi-Year Supply Agreement: Implications for the Semiconductor Market
AXT Inc. inks a three-year deal with Coherent, signaling growth potential in the semiconductor market driven by AI deman…
AbbVie’s Skyrizi Gets FDA Green Light for Pediatrics: A Game Changer for Growth Investors
AbbVie (ABBV) stock rose 3.44% following FDA approval for Skyrizi's pediatric use, signaling potential revenue growth.
CRISPR Therapeutics and Vertex Pharmaceuticals Gain FDA Approval: What It Means for Investors
CRISPR Therapeutics and Vertex Pharmaceuticals see significant market movement following FDA approval for pediatric gene…